Immune-related adverse events in patients with preexisting myasthenia gravis and thymoma following immune checkpoint inhibitor treatment: a retrospective, observational study
ObjectiveImmune checkpoint inhibitors (ICIs) can induce immune system activation and cause immune-related adverse events (irAEs). This study aimed to assess the incidence and management of irAEs in thymoma patients with preexisting MG who received ICI …